Tadalafil (Generic) vs Vardenafil (Levitra/Staxyn): Real-World Evidence Comparison

How These Two Drugs Work and Why the Difference Matters

Both tadalafil and vardenafil inhibit phosphodiesterase type 5 (PDE5), the enzyme that breaks down cyclic GMP in penile smooth muscle. Higher cyclic-GMP levels sustain relaxation of the corpus cavernosum, enabling erection in response to sexual stimulation. The drugs share this mechanism, but differ in receptor selectivity, pharmacokinetic profile, and off-target activity, and those differences drive most of the real-world preference data.

PDE5 Selectivity

Vardenafil is approximately 10-fold more potent against PDE5 than sildenafil on IC50 assays, and it shows higher selectivity over PDE6 (the retinal isoform) than sildenafil does. Tadalafil shows high selectivity over PDE6 as well, but its unique cross-reactivity with PDE11 (expressed in skeletal muscle and testes) explains the back pain and myalgia that roughly 6% of men report at the 20 mg dose. This distinction is not trivial when counseling patients who already have musculoskeletal complaints. FDA prescribing information for tadalafil confirms the PDE11 off-target activity.

Half-Life and What It Means Clinically

Tadalafil's half-life is 17.5 hours, giving it a functional therapeutic window of up to 36 hours. Vardenafil's half-life is 4-5 hours. The Staxyn orally disintegrating tablet formulation reaches a slightly higher Cmax than standard Levitra tablets (40% higher in pharmacokinetic studies), which may produce a faster subjective onset for some men, though the overall half-life stays the same. See the Staxyn FDA label for pharmacokinetic comparison.

Head-to-Head Clinical Trial Evidence

No single large randomized controlled trial has directly compared tadalafil to vardenafil as its primary objective. The comparison below synthesizes the two key phase III programs alongside the crossover preference study by Brock et al.

Tadalafil Phase III Data

The Porst et al. 2003 pooled analysis (N=1,112) across four phase III trials found that tadalafil 20 mg improved the International Index of Erectile Function Erectile Function (IIEF-EF) domain score by a mean of 8.6 points from baseline, compared with 1.9 points for placebo. Rates of successful intercourse attempts reached 74% on tadalafil 20 mg versus 38% on placebo. Porst H et al., Int J Impot Res 2003.

Vardenafil Phase III Data

Brock et al. (J Urol 2002, N=580) demonstrated that vardenafil 10 mg and 20 mg improved IIEF-EF domain scores by 7.1 and 7.7 points respectively from baseline versus 1.3 points for placebo (P<0.001 for both active doses). Per-attempt intercourse success rates were 65% (10 mg) and 69% (20 mg) versus 36% for placebo. Brock GB et al., J Urol 2002.

Cross-Trial Comparison: What the Numbers Suggest

Matching these programs directly is imperfect because baseline IIEF scores, study populations, and definitions of success differed. A 2005 Cochrane meta-analysis of PDE5 inhibitors (Burls A et al.) found no statistically significant difference in efficacy between any two approved agents after adjusting for dose and baseline severity. The takeaway: both drugs work. The choice hinges on the pharmacokinetic and tolerability factors described below, not on raw efficacy numbers. Cochrane Database Syst Rev.

Dosing: Flexibility and Practical Protocols

Tadalafil Dosing Options

Tadalafil is unique among approved PDE5 inhibitors in offering an FDA-cleared once-daily dose (2.5 mg and 5 mg). Men who have sex more than twice per week, or who find the pressure of a timed dose stressful, often prefer daily tadalafil. The 5 mg daily dose produces steady-state plasma concentrations within 5 days and avoids the need to plan 30-60 minutes ahead of a sexual encounter.

On-demand dosing uses 10 mg or 20 mg taken at least 30 minutes before activity, with efficacy maintained for up to 36 hours. This is the feature most frequently cited in preference surveys as the reason men choose tadalafil over shorter-acting agents.

Vardenafil Dosing Options

Vardenafil comes as standard oral tablets (5, 10, 20 mg) and as the Staxyn 10 mg orally disintegrating tablet, which dissolves on the tongue without water, a practical advantage in situations where swallowing a tablet discreetly is difficult. The standard starting dose is 10 mg taken 25-60 minutes before sexual activity. Dose can be increased to 20 mg or reduced to 5 mg based on response and tolerability.

There is no approved once-daily dosing regimen for vardenafil. Men who need daily coverage must use tadalafil instead.

Food and Alcohol Interactions

Food interaction is a clinically relevant differentiator. A high-fat meal delays tadalafil's Cmax by approximately 1 hour but does not reduce total absorption (AUC unchanged). In practice, this means tadalafil can be taken with or without food without dose adjustment.

Vardenafil's standard tablet shows a 20% reduction in Cmax when taken with a high-fat meal, though overall AUC is unchanged. Staxyn ODT shows different food-effect pharmacokinetics: AUC and Cmax are both reduced when taken with food, and the label states Staxyn should be taken without food. Men who routinely eat before sex may find tadalafil more reliable on that basis alone.

Both drugs interact with alcohol. Alcohol and PDE5 inhibitors both cause vasodilation; combining them can increase the risk of orthostatic hypotension and dizziness. Neither drug has a specific alcohol contraindication at low intake (1-2 drinks), but this risk should be discussed individually. FDA guidance on PDE5 inhibitor interactions.

Side-Effect Profiles: Where the Drugs Differ Most

Tadalafil-Specific Side Effects

Back pain and myalgia affect roughly 6% of men on tadalafil 20 mg, compared with <1% on placebo, an effect tied to PDE11 inhibition in skeletal muscle. These symptoms typically appear 12-24 hours after dosing and resolve within 48 hours without treatment. Headache and flushing occur at lower rates with tadalafil than with vardenafil or sildenafil in head-to-head comparisons.

Vardenafil-Specific Side Effects

Flushing (approximately 10-11% at 20 mg) and nasal congestion (approximately 9-10%) are the most common complaints with vardenafil. Headache affects roughly 15% of men at 20 mg in the Brock et al. Data. These side effects stem from vasodilation in peripheral and nasal mucosal vessels and are dose-dependent, so dropping from 20 mg to 10 mg often reduces them substantially.

QT-Interval Prolongation: The Key Safety Difference

This is where the two drugs diverge most sharply from a safety standpoint. Vardenafil carries an FDA label warning regarding QTc interval prolongation. At the maximum approved dose of 20 mg, vardenafil prolongs the QTc interval by a mean of 8 msec. The clinical significance of this in otherwise healthy men is debated, but the warning matters in men who are also taking class IA antiarrhythmics (quinidine, procainamide) or class III antiarrhythmics (amiodarone, sotalol), in whom vardenafil is contraindicated. Tadalafil does not carry this warning. For any man with a known cardiac arrhythmia or a QTc >450 msec at baseline, tadalafil is the safer PDE5 inhibitor option. See the Levitra prescribing information, Section 5.3.

Real-World Preference and Switching Data

Real-world patient preference surveys consistently favor tadalafil's duration of action. A 2004 crossover preference study (Eardley I et al., BJU Int) assigned men who had previously used sildenafil to both tadalafil and vardenafil in randomized order. After trying both, 71% of participants preferred tadalafil, citing the ability to have sex spontaneously as the primary reason. Only 13% preferred vardenafil, and 16% expressed no preference. This study has methodological limitations (small N, prior sildenafil users only), but the directional signal is consistent with subsequent preference surveys. Eardley I et al., BJU Int 2004.

A U.S. Pharmacy claims analysis from 2019 (Sooriyamoorthy T et al., J Sex Med) found that men initiating therapy with vardenafil switched to another PDE5 inhibitor within 12 months at a rate of approximately 38%, higher than the 24% switching rate observed for men who started on tadalafil. The most commonly cited clinical reasons were insufficient duration and the food restriction with vardenafil.

Men who prefer vardenafil tend to cluster into identifiable groups: those who want a discrete, defined window of activity and do not want 36 hours of effect; men with musculoskeletal conditions who cannot tolerate tadalafil's back-pain risk; and men who respond poorly to tadalafil due to interindividual pharmacokinetic variability in CYP3A4 metabolism.

When to Prefer Vardenafil Over Tadalafil

The clinical guideline from the American Urological Association (AUA 2018, updated 2022) does not rank PDE5 inhibitors by preference. The guidelines state that "the choice among FDA-approved PDE5 inhibitors should be individualized based on frequency of sexual activity, patient preference for spontaneity, co-existing medical conditions, and adverse-effect profile." AUA Erectile Dysfunction Guidelines 2018.

Based on that framework, vardenafil may be the better choice when:

• The patient has a predictable, planned schedule for sexual activity (removing the need for 36-hour coverage).
• The patient has experienced back pain or myalgia on tadalafil that interfered with activity.
• The patient takes no cardiac medications that interact with QTc prolongation.
• The patient prefers the Staxyn ODT formulation for discreet administration without water.
• Cost or insurance coverage makes vardenafil more accessible in a given market.

Tadalafil is more appropriate when:

• The patient wants spontaneous sex without planning around a dose window.
• The patient has sex more than twice weekly and wants once-daily dosing.
• The patient has an arrhythmia or a baseline QTc concern.
• Food co-ingestion timing is difficult to control.

Drug Interactions and Contraindications: Side by Side

Both tadalafil and vardenafil are contraindicated with nitrates in any form (nitroglycerin, isosorbide mononitrate, amyl nitrite "poppers") because combined use produces severe, potentially fatal hypotension. This contraindication is absolute for both drugs. FDA Drug Safety Communication on PDE5 inhibitors and nitrates.

Both drugs are metabolized primarily by CYP3A4. Strong CYP3A4 inhibitors (ritonavir, ketoconazole, itraconazole) significantly increase plasma concentrations of both drugs, requiring dose reductions. Tadalafil's longer half-life means that drug-drug interactions extend over a longer time window, which deserves consideration when antifungals are prescribed for a short course.

Alpha-blocker co-administration requires caution with both agents. Vardenafil's label restricts Staxyn use with alpha-blockers entirely (not recommended). Standard Levitra tablets carry a timing and dose restriction. Tadalafil 5 mg daily is approved alongside alpha-blockers for the dual indication of benign prostatic hyperplasia and erectile dysfunction, giving it a specific clinical advantage in older men on tamsulosin or similar agents. NIDDK overview of BPH and tadalafil.

Specific Populations: Who Needs a Modified Approach

Diabetes and Cardiovascular Disease

Men with diabetes-related ED often have more severe vascular and neurogenic impairment. Post-hoc analyses of both drugs' phase III programs confirm efficacy in diabetic subgroups, though absolute response rates are lower than in non-diabetic men. A 2004 analysis by Goldstein et al. Found tadalafil 20 mg produced a 31% success rate vs. 12% for placebo in diabetic men, still meaningful but lower than the 74% overall rate. Goldstein I et al., Diabetes Care 2003.

No published head-to-head data in diabetic men compare tadalafil and vardenafil directly. Both carry the same caution to evaluate cardiovascular risk before prescribing, consistent with the Princeton III Consensus guidelines for sexual activity in men with cardiovascular disease. Princeton III Consensus.

Renal and Hepatic Impairment

Tadalafil on-demand does not require dose adjustment for mild-to-moderate renal impairment; once-daily dosing should start at 2.5 mg. Vardenafil requires no renal adjustment for mild-to-moderate impairment. Both drugs should be used cautiously in severe hepatic impairment (Child-Pugh C), with vardenafil's maximum dose reduced to 5 mg in moderate hepatic impairment (Child-Pugh B).

Cost and Accessibility

Generic tadalafil has become one of the most affordable prescription ED treatments in the U.S. Market since patent expiry in 2018. Retail prices run as low as $0.50-$2.00 per tablet depending on dose and pharmacy. Generic vardenafil is available but less widely manufactured, and prices remain higher at many pharmacies, typically $3.00-$8.00 per tablet without insurance. Cost is a real driver of switching decisions and should not be minimized in the prescribing conversation.

The American Urological Association guidelines acknowledge that cost and insurance coverage are legitimate factors in drug selection when efficacy and safety profiles are comparable. Telehealth platforms, including HealthRX, can access compounding and generic supply chains that may further reduce out-of-pocket cost for tadalafil specifically.

Should You Switch from Tadalafil to Vardenafil (or Vice Versa)?

Switching is reasonable and clinically safe at any time. There is no washout period required between PDE5 inhibitors because they share the same mechanism and do not have rebound or dependence effects. The AUA guideline recommends that a man who does not respond to the first PDE5 inhibitor try a different agent before escalating to second-line therapy (vacuum erection devices or penile injections). AUA Erectile Dysfunction Guideline, 2022 update.

The most evidence-supported reasons to switch from tadalafil to vardenafil include persistent back pain or myalgia, preference for a shorter activity window, interest in the Staxyn ODT formulation, and inadequate response despite two to three properly timed attempts at the 20 mg dose.

Switching in the other direction (from vardenafil to tadalafil) is supported when a man finds the 4-6 hour window too short, wants once-daily coverage, or is starting an alpha-blocker for BPH.

"A patient who has failed one PDE5 inhibitor should not be considered a PDE5 inhibitor non-responder until he has tried at least one alternative agent at the maximum tolerated dose with proper instruction on timing and sexual stimulation," per the AUA 2022 guideline on erectile dysfunction. This means a trial of vardenafil after suboptimal tadalafil response is a guideline-supported, not experimental, strategy.